PGEN Precigen, Inc.

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

$2.22  +0.20 (9.90%)
As of 10/04/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  208,150,021
Average volume:  1,152,776
Market cap:   $441,278,045
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKM5C84
Valuation   (See tab for details)
PE ratio:   -4.47
PB ratio:   5.67
PS ratio:   3.96
Return on equity:   -127.44%
Net income %:   -84.48%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy